HLS Therapeutics Inc. (TSE:HLS – Get Free Report)’s share price hit a new 52-week low during trading on Thursday . The company traded as low as C$3.78 and last traded at C$3.77, with a volume of 287090 shares traded. The stock had previously closed at C$3.98.
Analysts Set New Price Targets
HLS has been the subject of several recent research reports. Raymond James Financial upgraded HLS Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the company from C$7.00 to C$8.00 in a research report on Friday. Canaccord Genuity Group upgraded shares of HLS Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Strong Buy” and a consensus target price of C$8.00.
Check Out Our Latest Research Report on HLS
HLS Therapeutics Trading Up 0.8%
HLS Therapeutics (TSE:HLS – Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported C($0.03) earnings per share for the quarter. HLS Therapeutics had a negative return on equity of 14.39% and a negative net margin of 15.26%.The firm had revenue of C$14.67 million for the quarter. During the same period in the prior year, the company posted ($0.09) EPS. As a group, equities research analysts expect that HLS Therapeutics Inc. will post -0.12 earnings per share for the current fiscal year.
About HLS Therapeutics
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.
Further Reading
- Five stocks we like better than HLS Therapeutics
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
- AirJoule Technologies: Short Squeeze Setup Amid Rising Risks
- MarketBeat Week in Review – 08/10 – 08/14
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
